Theralase Technologies

0

Photo Dynamic Therapy (“PDT”) Division Complete:  4Q2015 - Health Canada Clinical Trial Application (“CTA”) Approval and University Health Network Research Ethics Board (“UHN REB”) Approval Pending:  3Q2016 - Health Canada Investigational Testing Authorization (“ITA”) Approval and commence enrolling patients into Health Canada Phase Ib clinical study for NMIBC  4Q2016 - FDA pre-Investigational New Drug Application (“IND”) Approval for NMIBC  1Q2017 - Commence enrolling patients into Health Canada Phase Ib clinical study for brain cancer and  commence enrolling patients into FDA Phase Ib clinical study for lung cancer  2Q2017 - Complete Health Canada Phase Ib clinical study for NMIBC  3Q2017 - Commence enrolling subjects into Health Canada / FDA / CE Phase IIb clinical study for NMIBC  4Q2017 - FDA pre-Investigational New Drug Application (“IND”) Approval for lung and brain cancer  4Q2017 - Complete Health Canada Phase Ib clinical study for brain cancer and FDA Phase Ib clinical study for lung cancer  1Q2018 - Commence enrolling patients into Health Canada / FDA / CE Phase Ib clinical study for brain cancer and lung cancer  2Q2019 - Complete Health Canada / FDA / CE Phase IIb clinical study for NMIBC  4Q2020 - Complete Health Canada / FDA / CE Phase Ib clinical study for brain cancer and lung cancer

Please login to post a reply
Gramps1996
City
Rank
Vice President
Activity Points
7690
Rating
Your Rating
Date Joined
10/13/2007
Social Links
Private Message
Theralase Technologies
Symbol
TLT
Exchange
TSX-V
Shares
107,047,360
Industry
Technology & Medical
Website
Create a Post